CareLit · DOI-Nachweis · Zeitschrift für Gastroenterologie
High virologic response rate at End of Treatment (EOT) following triple therapy of previously untreated HCV Genotype 1 (G1) infection with boceprevir in German real-life
DOI 10.1055/s-0034-1386302
Bibliografische Angaben
Nachweis in CareLit
Autor:innenP Buggisch, H Löhr, G Teuber, H Steffens, M Kraus, C John, P Geyer, B Weber, T Witthoeft, A Herrmann, M Hoesl, U Naumann, T Dahhan, D Hartmann, B Dreher, M Bilzer
ZeitschriftZeitschrift für Gastroenterologie
Ausgabe08/2014
Jahrgang / SeitenNicht angegeben
Kernaussage aus der Literatur
Abstract-Vorschau
Background: Triple therapy with the HCV protease inhibitor boceprevir has been approved as new standard of care for patients with chronic HCV G1 infection. The NOVUS observational study was conducted to investigate the efficacy of this novel antiviral therapy in German real-life. Methods: From April 2012 until January 2014, 536 patients with G1 infection were recruited in the ongoing NOVUS study by 97 practices and…
Zitieren
Zitierempfehlung
P Buggisch, H Löhr, G Teuber, H Steffens, M Kraus, C John, P Geyer, B Weber, T Witthoeft, A Herrmann, M Hoesl, U Naumann, T Dahhan, D Hartmann, B Dreher, M Bilzer (2014) High virologic response rate at End of Treatment (EOT) following triple therapy of previously untreated HCV Genotype 1 (G1) infection with boceprevir in German real-life. Zeitschrift für Gastroenterologie (08). https://doi.org/10.1055/s-0034-1386302
Mit CareLit weiterarbeiten